Michael Gelband’s Vanguard Intermediate-Term Corporate Bond ETF VCIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$25M Buy
+302,920
New +$25M 0.16% 96
2024
Q3
Sell
-20,786
Closed -$1.66M 2125
2024
Q2
$1.66M Buy
+20,786
New +$1.65M 0.01% 850
2023
Q2
Sell
-11,300
Closed -$906K 2273
2023
Q1
$906K Buy
+11,300
New +$896K 0.01% 1172
2021
Q4
Sell
-8,500
Closed -$802K 2622
2021
Q3
$802K Sell
8,500
-16,800
-66% -$1.6M 0.01% 1130
2021
Q2
$2.4M Buy
25,300
+20,299
+406% +$1.91M 0.03% 597
2021
Q1
$465K Buy
+5,001
New +$475K 0.01% 1425
2020
Q4
Sell
-11,642
Closed -$1.11M 2402
2020
Q3
$1.11M Buy
11,642
+90
+0.8% +$8.65K 0.02% 635
2020
Q2
$1.1M Buy
+11,552
New +$1.06M 0.03% 696
2020
Q1
Sell
-4,682
Closed -$428K 1666
2019
Q4
$428K Buy
+4,682
New +$427K 0.01% 958

Other funds holding VCIT

Michael Gelband's VCIT Position: Q2 2026 in Review

Michael Gelband opened a new position in Vanguard Intermediate-Term Corporate Bond ETF (VCIT) in Q2 2026: 302,920 shares worth $25M. The stake represents 0.16% of the portfolio and ranks #96 among its holdings. This is a return to the name: Michael Gelband previously reported a position in VCIT as recently as Q2 2024.

Michael Gelband first reported a position in VCIT in Q4 2019 and has held it in 9 quarters since. 1,353 funds tracked by Wall St. Rank hold VCIT as of Q2 2026.

  • Michael Gelband held 302,920 shares of Vanguard Intermediate-Term Corporate Bond ETF worth $25M as of Q2 2026.
  • Vanguard Intermediate-Term Corporate Bond ETF was a new Michael Gelband position in Q2 2026.
  • Vanguard Intermediate-Term Corporate Bond ETF made up 0.16% of Michael Gelband's portfolio in Q2 2026, its #96 holding.
  • Michael Gelband first reported a position in Vanguard Intermediate-Term Corporate Bond ETF in Q4 2019 and has held it in 9 quarters since.
  • 1,353 funds tracked by Wall St. Rank held Vanguard Intermediate-Term Corporate Bond ETF as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.